🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation

RecruitingPhase 2Ages 18 Years - 80 YearsAllXyra, LLC
NCT07792239 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This multicenter, open-label study aims to assess the safety, tolerability and efficacy of budiodarone in treating participants with non-permanent AF, in particular paroxysmal atrial fibrillation (PAF). The trial will serve as a 6-month safety and a proof-of-concept study for a dose escalation strategy using AF monitoring, enrolling approximately 100 participants who will undergo 24 weeks of treatment. The study aims to evaluate the feasibility of dose escalation through AF monitoring of long episodes atrial fibrillation last 5 hours or longer.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Key Inclusion Criteria: * Proven paroxysmal atrial fibrillation or undergoing first-time elective electrical (direct current) cardioversion for persistent atrial fibrillation, or second-time elective electrical (direct current) cardioversion. * Baseline AF Criteria: To qualify for treatment, each participant must have during the 28-day baseline period an AFB greater than 5% and one of the following qualifying events: 1) 2 continuous AF episodes (LEAF) of 5 hours or longer; or 2) 2 rolling 24-hour periods in which cumulative AF duration is 5 hours or longer; or 3) 1 continuous AF episode (LEAF) of 5 hours or longer plus 1 rolling 24-hour period in which cumulative AF duration is 5 hours or longer * Must have failed at least one prior therapy for AF * Must have an AFSS greater than 3. * CHA₂DS₂-VASc score of 1 or more for males and 2 or more for females and be on oral anticoagulant for at least 3 weeks prior to receiving the study medication. * For participants with heart failure: NYHA Class I or II heart failure. Key Exclusion Criteria: * NYHA Class 3 or 4 heart failure. * MI, ischemic stroke, or any clinically relevant venous thromboembolism within 3 months of screening. * Unstable angina, percutaneous transluminal coronary angioplasty (PTCA), or CABG within 3 months of screening. * Prolonged QTcF Interval with a normal QRS duration (\>500 ms with QRS ≤120 ms). * Persistent AF (≥7 consecutive days or episodes \>23 hours). Those presenting with persistent AF at screening are eligible if they are scheduled to undergo first-time elective cardioversion, or second-time cardioversion * Recent treatment with rhythm control medications (Class I or III Singh-Vaughan Williams) within five half-lives before screening (rate control drugs permitted) and amiodarone within 3 months prior to screening. * Cardiac ablation procedures within 30 days of screening or participants who have scheduled an ablation procedure * Severe end-organ disease
💊

What it tests

  • Budiodarone 200 mg BID
  • Budiodarone 400 mg BID
  • Budiodarone 600 mg BID
  • Budiodarone 800 mg BID
📍

Where

4 sites
Oddział Kardiologiczny, Szpital Miejski Św. Wincentego a Paulo w Gdyni
Gdynia, Poland
Klinika Kardiologii
Krakow, Poland
EMED Centrum Usług Medycznych Ewa Śmiałek
Rzeszów, Poland
Klinika Kardiologii i Chorób Wewnętrznych Wojskowy Instytut Medyczny, Państwowy Instytut Badawczy
Warsaw, Poland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy